Search
Close this search box.

Blog

Homeopathy for Dupuytren’s

HH Reckeweg (1905-1985) in Germany developed the Disease Evolution Table of homeopathic medicine. In this system, Dupuytren’s contracture is classified as a mesenchymal-connective tissue cellular-degeneration phase disease. This should be the starting point for homeopathic physicians to begin developing a homeopathic cure for Dupuytren’s. See where Dupuytren’s fits on the

Read More »

Machines to Stretch Dupuytren’s Cords

There is not yet a perfect solution for PIP contractures from Dupuytren’s Disease, or for PIP contractures in general. One approach has been to use temporary skeletal fixation devices to slowly lengthen Dupuytren’s cords and scar tissue. The collagen bundles in Dupuytren’s cords don’t actually stretch: they remodel, disconnecting crosslinks

Read More »

Tissue markers for Dupuytren’s

Is it possible to predict the course of Dupuytren’s in an individual? Who will need surgery? Who will have rapid progression or an early recurrence after surgery and who won’t? Family and personal history provide general trends, but that’s all. Several studies have correlated the cellularity of nodule tissue and

Read More »

Treatment effectiveness for Dupuytren’s needs documentation

Progress into new territory requires an open mind: beware conformity; examine failure; engage outsiders, and be aware of undocumented claims. This interesting report of an injection treatment for Dupuytren’s would be worth considering if published in an independent peer reviewed format rather than on the manufacturer’s web site: https://www.dupuytrens.org/DupPDFs/2001_Beller.pdf

Read More »

Rock Climbing and Dupuytren’s – an interesting analysis

Dupuytren’s is an inherited systemic disorder of either the threshold or the feedback inhibition of the biology of scar formation, contracture and maturation. It is not spontaneous, but triggered in specific areas having the common characteristic of being subjected to repeated high shearing or stretching forces: palmar fascia, plantar fascia,

Read More »

How the FDA sees Collagenase for Dupuytren’s

Why is it taking so long for collagenase injection treatment to be available to treat Dupuytren’s? Trials have been ongoing for over 10 years. The answer: collagenase is an extremely potent substance, and the FDA has required very detailed proof not only that it works, but that it is safe,

Read More »

Abstracts can be misleading

Unlike proximal interphalangeal joint contractures from Dupuytren’s, metacarpophalangeal joint contractures usually respond so well to fasciectomy or fasciotomy that joint capsule or ligament release is generally not a consideration. Because of this, I was intrigued by the title of this report: a series of patients treated with dermofasciectomy and MP

Read More »

Myofibroblast Biology

Myofibroblast biology is at the heart not only of Dupuytren’s, but of other diseases not related to Dupuytren’s. Myofibroblasts are major players in pulmonary fibrosis, cirrhosis, renal fibrosis and arteriosclerosis. Studies of myofibroblast biology in these conditions may shed light on potential new treatment strategies for Dupuytren’s. Gains in the

Read More »